NASDAQ:ANGO - AngioDynamics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.00
  • Forecasted Upside: 81.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$19.89
▲ +0.79 (4.14%)

This chart shows the closing price for ANGO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AngioDynamics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANGO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANGO

Analyst Price Target is $36.00
▲ +81.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for AngioDynamics in the last 3 months. The average price target is $36.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 81.00% upside from the last price of $19.89.

This chart shows the closing price for ANGO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in AngioDynamics. This rating has held steady since August 2021, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2020
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2021
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2021
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/31/2021
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/29/2021
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/27/2022
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/28/2022
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/28/2022

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/8/2022Canaccord Genuity GroupBoost Price Target$34.00 ➝ $40.00Medium
8/20/2021OppenheimerInitiated CoverageMarket PerformLow
7/9/2021Raymond JamesBoost Price TargetStrong-Buy$27.00 ➝ $32.00High
3/29/2021Raymond JamesReiterated RatingBuyLow
1/8/2021Raymond JamesBoost Price TargetStrong-Buy$18.00 ➝ $24.00High
11/26/2020Raymond JamesReiterated RatingHold ➝ NeutralLow
11/25/2020Raymond JamesUpgradeMarket Perform ➝ Strong-Buy$18.00High
10/4/2019KeyCorpLower Price TargetOverweight$30.00 ➝ $21.00High
7/11/2018Raymond JamesDowngradeOutperform ➝ Market PerformHigh
4/3/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$16.33Medium
4/3/2018UBS GroupUpgradeMarket Perform ➝ OutperformMedium
1/5/2018Craig HallumDowngradeBuy ➝ HoldHigh
9/29/2017KeyCorpReiterated RatingHoldHigh
8/25/2017KeyCorpReiterated RatingHoldLow
7/19/2017BarclaysLower Price TargetEqual Weight$17.00 ➝ $16.00Low
7/4/2017Cantor FitzgeraldBoost Price TargetOverweight$20.00 ➝ $21.00Low
(Data available from 5/28/2017 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2021
  • 4 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
11/29/2021
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
12/29/2021
  • 2 very positive mentions
  • 6 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
1/28/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/27/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/29/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/28/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/28/2022

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
AngioDynamics logo
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Read More

Today's Range

Now: $19.89
Low: $19.08
High: $20.11

50 Day Range

MA: $21.31
Low: $17.98
High: $24.49

52 Week Range

Now: $19.89
Low: $17.56
High: $32.00

Volume

146,881 shs

Average Volume

289,844 shs

Market Capitalization

$770.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of AngioDynamics?

The following equities research analysts have issued reports on AngioDynamics in the last twelve months: Canaccord Genuity Group Inc., Oppenheimer Holdings Inc., Raymond James, StockNews.com, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for ANGO.

What is the current price target for AngioDynamics?

0 Wall Street analysts have set twelve-month price targets for AngioDynamics in the last year. Their average twelve-month price target is $36.00, suggesting a possible upside of 81.0%.
View the latest price targets for ANGO.

What is the current consensus analyst rating for AngioDynamics?

AngioDynamics currently has 1 hold rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ANGO will outperform the market and that investors should add to their positions of AngioDynamics.
View the latest ratings for ANGO.

How do I contact AngioDynamics' investor relations team?

AngioDynamics' physical mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier's listed phone number is (518) 795-1400 and its investor relations email address is [email protected] The official website for AngioDynamics is www.angiodynamics.com. Learn More about contacing AngioDynamics investor relations.